| Similar Articles |
 |
Chemistry World January 5, 2007 Victoria Gill |
PEG Makes Cheaper Drugs for Developing Countries UK and Indian scientists have embarked on a collaboration to develop a new protein-based treatment for hepatitis C, which they say will provide an affordable drug urgently needed in countries where resources are limited.  |
BusinessWeek November 24, 2003 John Carey |
Barring The Door Against AIDS A new generation of drugs focuses on keeping the virus from entering cells.  |
The Motley Fool August 10, 2010 Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.  |
Chemistry World June 2008 Sarah Houlton |
Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success  |
The Motley Fool March 31, 2011 Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones?  |
The Motley Fool September 8, 2010 Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win.  |
Chemistry World November 2, 2009 Simon Hadlington |
New way to find drugs' unintended targets Researchers in the US have devised a new way to predict 'off-target' effects for pharmaceutical drugs.  |
The Motley Fool July 27, 2011 Brian Orelli |
Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication.  |
Chemistry World November 25, 2008 James Urquhart |
Virus revealed by flipping lipid A drug that flags up virus-infected cells for destruction by the body's own immune system could lead to new, broad-spectrum anti-viral treatments, say US scientists.  |
The Motley Fool October 31, 2011 Brian Orelli |
Gunning for the Leaders Hepatitis C drugs take center stage.  |
HHMI Bulletin May 2010 Sarah C.P. Williams |
Lab-Grown Liver New cell culture system solves problem of growing liver cells.  |
Chemistry World December 9, 2009 Sarah Houlton |
New hep C breakthrough A drug being developed by Denmark's Santaris Pharma could provide a breakthrough in the treatment of hepatitis C, and positive results in a study on chimpanzees point to its potential to avoid drug resistance.  |
The Motley Fool April 17, 2008 Brian Lawler |
The End for (Another) Hepatitis C Drug Candidate ViroPharma stops development of its compound after data showed it may hurt the liver.  |
The Motley Fool October 19, 2007 Brian Lawler |
Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down.  |
Chemistry World September 1, 2008 James Mitchell Crow |
Drug discovery on a chip Scientists in the US have, for the first time, used microfluidics to discover drug leads. The team's lab-on-a-chip device revealed inhibitors of a key membrane-bound protein in hepatitis C virus  |
Nurse Practitioner December 2009 Gujral & Collantes |
Understanding Viral Hepatitis: A guide for primary care Recent advancements in the field of genomics and proteomics technology have given researchers and clinicians more insight on disease pathogenesis and helped create more tailored approaches to the treatment of these conditions.  |
The Motley Fool December 16, 2011 Brian Orelli |
Safety (Still) Trumps Acquisitions in Hep C Pharmasset announced it was discontinuing all treatment arms in one of its phase 2b trials that contain the drug PSI-938. The drug candidate caused laboratory abnormalities in tests associated with liver function.  |
Chemistry World April 21, 2010 Sarah Houlton |
Fresh hep C hope A new kind of compound to treat hepatitis C is showing promise in early clinical trials.  |
American Family Physician June 15, 2006 Brundage & Fitzpatrick |
Hepatitis A The introduction of hepatitis A vaccines in 1995 led to a drop in the number of reported cases of hepatitis A and a shift to a higher percentage of cases occurring in older age groups. The hepatitis A virus survives for extended periods in the environment.  |
American Family Physician November 1, 2001 Thomas R. Riley |
Preventive Strategies in Chronic Liver Disease Chronic liver disease is the 10th leading cause of death in the United States. Preventive care can significantly reduce the progression of liver disease. Part I: Alcohol, Vaccines, Toxic Medications and Supplements, Diet and Exercise...  |
The Motley Fool April 26, 2011 Brian Orelli |
There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost.  |
The Motley Fool March 28, 2008 Brian Orelli |
The Yin and Yang of Schering's Label Changes Schering gets a pair of label changes that have opposite effects for its hepatitis C drug.  |
American Family Physician January 1, 2004 Lin & Kirchner |
Hepatitis B Hepatitis B causes significant morbidity and mortality worldwide. Effective vaccines for hepatitis B virus have been available since 1982; infant and childhood vaccination programs introduced in the 1990s have resulted in a marked decrease in new infections.  |
American Family Physician January 1, 2004 |
Hepatitis B Infection What is hepatitis B virus?... How can I tell if I have HBV infection?... What happens after HBV infection?... What health problems can chronic HBV infection cause?... How can I protect my liver if I have chronic HBV infection?... How can HBV infection be prevented?... etc.  |
Chemistry World June 12, 2014 Philli Broadwith |
Merck & Co bolsters hepatitis C pipeline with Idenix acquisition US drug firm Merck & Co has agreed to buy hepatitis C specialist Idenix for $3.85 billion.  |
Pharmaceutical Executive December 1, 2005 Ron Feemster |
The PharmExec 2005 Pipeline Report Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and -- at last -- innovative mechanisms for troublesome targets: Acomplia [rimonabant] by Sanofi-Aventis... AMG 162 [denosumab] by Amgen... etc.  |
The Motley Fool August 10, 2007 Brian Lawler |
ViroPharma Whacked by Data Shares of ViroPharma fall after safety issues come to light with one of its drugs. A phase 2 study of their hepatitis C antiviral medication has been halted, with only a slim chance of starting up again.  |
Chemistry World April 2009 Derek Lowe |
Column: In the pipeline The author considers the problems of addressing drug development out of sequence  |
Chemistry World July 26, 2012 Derek Lowe |
Screen shots You might not think that the makeup of a compound screening collection could set off many arguments, but there are a few issues there that will do the trick almost every time.  |
The Motley Fool May 28, 2010 Brian Orelli |
Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree.  |
Chemistry World November 2009 Derek Lowe |
Column: In the pipeline The author advises opening your mind during the screening cascade taken by potential drug targets, and remaining goal orientated at all times  |
The Motley Fool July 7, 2011 Brian Orelli |
J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo.  |
The Motley Fool June 27, 2008 Brian Lawler |
Difficult Obstacles for SciClone With all the new technologies and discoveries, some drugmakers are undoubtedly going to be left in the dust. SciClone Pharmaceuticals, with its lead drug Zadaxin, might be one such drugmaker.  |
Chemistry World October 2008 Derek Lowe |
Column: In the pipeline The author seeks a cure for 'compound bloat'  |
Chemistry World October 31, 2008 Matt Wilkinson |
GSK Snaps up Hepatitis Drug Developer In a bid to strengthen its efforts to develop new hepatitis therapies, GSK has agreed to buy Genelabs Technologies in a deal worth $57 million.  |
The Motley Fool January 30, 2009 Brian Orelli |
Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients.  |
The Motley Fool September 27, 2005 Jack Uldrich |
A Ray of Hope for Flamel? New hepatitis C treatment offers a ray of hope to the ailing nanotech company. Unfortunately, this news does not guarantee sunnier days ahead.  |
The Motley Fool April 19, 2004 Charly Travers |
4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry.  |
The Motley Fool April 29, 2008 Brian Lawler |
So Pharmasset, So Good Early data hints at a promising hepatitis C treatment.  |
Reactive Reports Issue 41 David Bradley |
Chip Chops Time off Drug Discovery Process A next-generation optical screening platform can screen a vast number of compounds rapidly by passing wave after wave of compounds in solution over the surface of the biochip.  |
The Motley Fool January 9, 2012 Travis Hoium |
Idenix Pharmaceuticals Shares Jumped: What You Need to Know Shares of Idenix Pharmaceuticals got a positive diagnosis today and climbed 43% after the company released positive data for its hepatitis C drug.  |
The Motley Fool May 15, 2008 Brian Lawler |
What's Cooking at Flamel? The drugmaker makes finding partners to help pay for its hepatitis C and diabetes compounds a top priority.  |
Pharmaceutical Executive February 1, 2006 Ron Feemster |
Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets.  |
The Motley Fool June 14, 2011 Brian Orelli |
Going for Seconds in the Hepatitis C Space Fresh from the Food and Drug Administration's approval of its hepatitis C drug, Incivek, Vertex has licensed a pair of hepatitis C compounds from privately held Alios BioPharma.  |
The Motley Fool March 4, 2009 Brian Orelli |
Vertex Combines to Keep From Being Ground Up Vertex Pharmaceuticals announces that it is buying ViroChem Pharma, getting two early stage hepatitis C compounds in the deal.  |
Chemistry World April 2011 |
Column: In the Pipeline If you look over the whole pharmacopeia, you'll see there are a lot of compounds that got their start as natural products.  |
Chemistry World December 2008 |
Column: In the pipeline I've worked on two drug discovery efforts (one right after the other, as fate would have it) whose final compounds differed by essentially one methyl group from the starting points of each project.  |
Chemistry World September 16, 2008 Hepeng Jia |
Research Initiative Targets China's Major Killer Diseases A new epidemics research initiative is targeting China's biggest killer diseases: HIV/AIDS, tuberculosis (TB) and virulent hepatitis.  |
American Family Physician June 15, 2006 |
Hepatitis A: What You Should Know A patient guide: What is hepatitis A?... How is the disease spread?... How can I tell if I have the disease?... How is this disease treated?... How long will I be contagious?... etc.  |
Chemistry World June 2011 |
Column: In the pipeline Chemists are human. Humans are hierarchical. Therefore...well, therefore, you'll find a number of different roles and levels for scientists in a drug company's labs. Here's a rough ordering, from least experienced to most.  |